Infection Control, Antimicrobial Resistance, Chemoprophylaxis and Antimicrobial Stewardship Prolonged Dual Antibiotic Courses for Culture Positive Neonatal Sepsis in 3 Greek Neonatal Units

I. Kopsidas, L. Lianou, E. Kourkouni, K. Karachristou, E. Stratiki, A. Vintila, D. Karaviti, Z. Kirikas, L. Baglatzi, K. Mougkou, M. Pappa, M. Tsolia, T. Zaoutis, N. Spyridis
33rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2015)
Leipzig, Germany, May 12-16, 2015

BACKGROUND AND AIMS: Antimicrobial resistance (AMR) is a major healthcare problem. Antibiotic stewardship programs seek to promote judicious use of antimicrobials. One key element of stewardship interventions is to de-escalate empiric antibiotic therapy following positive culture results.
The aim of this study is to document dual antibiotic therapy in neonates following positive culture results in 3 neonatal units (NNUs) in Greece.

METHODS: These are preliminary results of an ongoing prospective antibiotic use surveillance study conducted in 3 NNUs in Athens, Greece. Data collected between March and September 2014 by indication at initiation of antibiotic administration. Cases with only an indication of sepsis were identified and Length of Therapy (LOT), Days of Therapy (DOT) and DOT/LOT were calculated. DOT/LOT ratio was used as a proxy for estimation of antibiotic de-escalation failure.

RESULTS: We documented 39 cases of neonates treated with the diagnosis of “sepsis”. Median LOT was 7(IQR: 6-10) days and DOT 14(IQR: 12-20) days. Neonates with culture negative sepsis were treated for a median of 7(IQR: 5-7) days vs 10(10-15) for those with culture positive sepsis (p=0.0053) (Table-1). 13 neonates (39%) had positive blood cultures. Redundant dual antibiotic therapy was given to 7/13(54%) following culture results, of which 6/7(86%) were gram positive isolates. Table-2 demonstrates antibiotics and isolates from neonates with positive culture results.

CONCLUSION: We documented prolonged dual antibiotic courses with extensive spectrum in 3 Greek NNUs even in the presence of susceptibility results following positive blood cultures. Narrowing antibiotic regimen is critical especially in neonatal units where broad and prolonged antibiotic courses are often documented.

Table 1 Antibiotic Use in days, Combined and by Culture Result

  Overall Culture negative Culture Positive
N 39 26 13
LOT (median-IQR) days 7(6-10) 7(5-7) 10(10-15)
DOT (median-IQR) days 14(12-20) 14(10-16) 19.5(17-22)
DOT/LOT (median-IQR) days 2 (1.6-2) 2(2-3) 1.47(1.27-2)

Length of Therapy (LOT) – the number of days during which at least one dose of any antibiotic was received.
Days of Therapy (DOT) – the aggregate sum of LOT for each antibiotic received

Table 2 Antibiotic Therapy and Isolates of Culture positive cases

  Day 1 Day 4
Pathogen AB1 AB2 AB3 AB1 AB2 AB3
klebsiella Meropenem Vancomycin   Meropenem *  
E.coli Piperacillin/
Tazobactam
teicoplanin   Piperacillin/
Tazobactam
teicoplanin  
klebsiella Meropenem Vancomycin   Meropenem *  
CONS Meropenem Vancomycin   * Vancomycin  
klebsiella Meropenem Vancomycin   Meropenem *  
Staphylococcus   epidermidis teicoplanin Ceftazidime   teicoplanin Ceftazidime  
CONS Ampicillin Vancomycin   Ampicillin Vancomycin  
Staph. hominis Vancomycin Amikacin   Vancomycin Amikacin  
Staph. haemolyticus Meropenem Vancomycin linezolid Meropenem Vancomycin linezolid
CONS Meropenem Vancomycin Amikacin Meropenem Vancomycin *
Staphylococcus spp linezolid     linezolid    
Enterococcus
+CONS(next day)
Meropenem Vancomycin Amikacin Meropenem Vancomycin *
Candida Micafungin     Micafungin    
             

(*) Discontinued antibiotics on or before Day 4 of Culture draw and initiation of therapy


Table 2 Antibiotic Therapy and Isolates of Culture positive cases
  Day 1 / Day 4

# of Antibiotics

on Day 4

Quantity Spectrum
Pathogen AB1 AB2 AB3
Klebsiella pneumoniae Meropenem Vancomycin   1    
E.Coli Pip/Tazo Teicoplanin   2    
Klebsiella pneumoniae Meropenem Vancomycin   1    
CONS Meropenem Vancomycin   1    
Klebsiella pneumoniae Meropenem Vancomycin   1    
Staph. Epidermidis Teicoplanin Ceftazidime   2    
CONS Ampicillin Vancomycin   2    
Staph. hominis Vancomycin Amikacin   2   *
Staph. haemolyticus Meropenem Vancomycin Linezolid 3    
CONS Meropenem Vancomycin Amikacin 2    
Staphylococcus spp Linezolid     1    
Enterococus+CONS Meropenem Vancomycin Amikacin 2    

Pip/Tazo : Piperacillin/Tazobactam; staph : Staphylococcus
Purple: Antibiotics discontinued before or on the 4th day
Red: Antibiotic use violation
Green: No violation